Suzhou Fushilai Pharmaceutical Co., Ltd. (SHE:301258)
China · Delayed Price · Currency is CNY 26.96
-0.15 (-0.55%)
At close: Sep 23, 2026
SHE:301258 Revenue
Suzhou Fushilai Pharmaceutical had revenue of 92.61M CNY in the quarter ending June 30, 2026, a decrease of -16.44%. This brings the company's revenue in the last twelve months to 394.29M, down -9.72% year-over-year. In the year 2025, Suzhou Fushilai Pharmaceutical had annual revenue of 432.73M with 0.76% growth.
Revenue (ttm)
394.29M
Revenue Growth
-9.72%
P/S Ratio
6.09
Revenue / Employee
730.17K
Employees
540
Market Cap
2.40B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 432.73M | 3.26M | 0.76% |
| Dec 31, 2024 | 429.47M | -59.82M | -12.23% |
| Dec 31, 2023 | 489.29M | -78.92M | -13.89% |
| Jan 1, 2023 | 568.21M | 46.52M | 8.92% |
| Jan 1, 2022 | 521.70M | 44.85M | 9.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Universal Biotech | 1.15B |
| Shandong Sito Bio-technology | 1.12B |
| Guangdong VTR Bio-Tech | 814.07M |
| Guiyang Xintian Pharmaceutical | 723.26M |
| Jilin Jian Yisheng Pharmaceutical | 650.83M |
| Hubei Goto Biopharm Group | 650.05M |
| Yantai Zhenghai Biotechnology | 336.07M |
| Shenzhen Bioeasy Biotechnology | 282.31M |